Trial Profile

Phase II Trial of Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Muzastotug (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

Most Recent Events

04 Mar 2025 New trial record
27 Feb 2025 According to an Adagene media release, this investigator-initiated trial is expected to begin patient enrollment in April 2025 and expected primary completion in mid-2027.
27 Feb 2025 According to an Adagene media release, Dr. Yong Wei Peng is the primary investigator of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com